CARDIOVASCULAR AND SAFETY EVALUATIONS OF POTENTIAL MEDICATIONS TO REDUCE DRUG USE

Release Date:  March 9, 2000

NOTICE:  DA-00-011

RFP AVAILABLE:  N01DA-0-8805

National Institute on Drug Abuse

The National Institute on Drug Abuse is soliciting proposals from qualified 
organizations having the in-house capacity to perform experiments in 
laboratory animals to systematically evaluate the cardiovascular and 
toxicological effects of potential treatment drugs, both new and marketed, for 
treatment of drug abuse.  Specifically, treatment drugs for two classes of 
drugs of abuse (stimulants and opiates) will be investigated pre-clinically. 
Due to the nature of the compounds which may be evaluated, it is mandatory 
that offerors possess a DEA Research Registration for Schedules II to V in 
order to handle substances under the Controlled Substances Act of 1970, and 
demonstrate the capability to obtain a DEA registration for Schedule I 
controlled substances. Further, all offerors must be in compliance with the 
NIH guidelines on the care and use of laboratory animals and, the laboratory 
must be operated according to the FDA’s Good Laboratory Practices Program.  It 
is estimated that a five-year incrementally funded level of effort type 
contract will result from this procurement.  The project will include options 
for additional effort to cover additional testing. RFP No. N01DA-0-8805 will 
be available electronically on or about March 27, 2000, and may be accessed 
through the NIDA website at the following address: (URL:  
http://www.nida.nih.gov/RFP/RFPList.html) Please note that the RFP for this 
acquisition will be streamlined to include only the Work Statement, 
Deliverables and Reporting Requirements, Special Requirements and Mandatory 
Qualifications, Technical Evaluation Criteria, and other necessary Proposal 
Preparation Instructions.  All information required for the submission of an 
offer will be contained in or accessible through the electronic RFP package.  
Response to the RFP will be due on or about May 25, 2000.  Any responsible 
offeror may submit a proposal which will be considered by the Government.  
This advertisement does not commit the Government to award a contract.  

Point of Contact:	Kenneth E. Goodling, Contracting Officer
National Institute on Drug Abuse, NIH
Contracts Management Branch, OPRM
6001 Executive Blvd., Room 3105, MSC 9543
Bethesda, Maryland 20892-9543
Electronic Mail Address: kg25d@nih.gov
Telephone: (301) 443-6677
Fax: (301) 443-7595 

Return to Volume Index

Return to NIH Guide Main Index

	Office of Extramural Research (OER)			National Institutes of Health (NIH) 9000 Rockville Pike Bethesda, Maryland 20892			Department of Health and Human Services (HHS)
Note: For help accessing PDF, RTF, MS Word, Excel, PowerPoint, Audio or Video files, see Help Downloading Files.